Samrat Pharmachem Complete Financial Statements
In FYNone, Samrat Pharmachem (SAMRATPH) reported revenue ₹290 Cr, net profit ₹-2 Cr and EPS ₹-5.40, with a net profit margin of 2.4% and ROE of 9.7%. Full financial statements from FY2015 to FY2025 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Samrat Pharmachem share price chart.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
SAMRATPH Revenue, Net Profit & EBITDA — Year-on-Year Growth
SAMRATPH YoY (March 2025 vs Period) — revenue +1.0%, net profit -128.6%, EBITDA -100.0%, expenses +5.1%. Explore SAMRATPH Benjamin Graham valuation to estimate fundamental worth using multiple valuation models.
SAMRATPH Income Statement — Revenue, EBITDA & Net Profit
Samrat Pharmachem revenue ₹290 Cr, EBITDA ₹0 Cr, net profit ₹-2 Cr, EPS ₹-5.40 (None) — net profit margin 2.4%. Review Samrat Pharmachem price earnings to evaluate earnings-based valuation against sector peers.
| Particulars | None | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 290 | 287 | 283 | 311 | 222 | 180 | 138 | 112 | 93 | 71 | 62 | 48 |
| Expenses | 290 | 276 | 279 | 287 | 198 | 170 | 131 | 108 | 87 | 67 | 61 | 46 |
| EBITDA | 0 | 11 | 4 | 24 | 25 | 9 | 7 | 4 | 6 | 4 | 1 | 2 |
| Operating Profit Margin % | 0.00% | 4.00% | 1.00% | 8.00% | 11.00% | 5.00% | 5.00% | 3.00% | 6.00% | 5.00% | 2.00% | 2.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | -2 | 10 | 3 | 23 | 24 | 7 | 6 | 2 | 5 | 3 | 0 | 1 |
| Tax | 0 | 3 | 0 | 6 | 6 | 2 | 2 | 1 | 2 | 1 | 0 | 0 |
| Net Profit | -2 | 7 | 2 | 17 | 17 | 5 | 4 | 2 | 3 | 2 | 0 | 0 |
| Earnings Per Share (₹) | -5.40 | 23.02 | 7.00 | 53.83 | 55.62 | 17.26 | 13.71 | 4.97 | 10.41 | 5.68 | 0.97 | 1.02 |
SAMRATPH Balance Sheet — Assets, Liabilities & Shareholders' Equity
SAMRATPH total assets ₹122 Cr, total equity ₹72 Cr, total liabilities ₹ Cr (2025) — ROE 9.7%.
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 122 | 122 | 117 | 85 | 57 | 58 | 40 | 41 | 36 | 36 | 26 |
| Current Assets | 103 | 103 | 99 | 71 | 47 | 50 | 33 | 33 | 28 | 28 | 19 |
| Fixed Assets | 11 | 11 | 11 | 10 | 9 | 7 | 7 | 7 | 7 | 7 | 7 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Investments | 4 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Other Assets | 107 | 108 | 104 | 75 | 48 | 50 | 33 | 34 | 29 | 27 | 19 |
| LIABILITIES | |||||||||||
| Total Liabilities | |||||||||||
| Current Liabilities | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 2 | 1 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | 72 | 65 | 63 | 47 | 30 | 24 | 20 | 19 | 15 | 14 | 14 |
| Share Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves & Surplus | 69 | 62 | 60 | 44 | 27 | 21 | 17 | 15 | 12 | 11 | 10 |
SAMRATPH Cash Flow Statement — Operating, Investing & Financing
Samrat Pharmachem operating cash flow ₹-10 Cr, investing ₹0 Cr, financing ₹1 Cr, net cash flow ₹-10 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -10 | 9 | -9 | 18 | 5 | -1 | 2 | 0 | -3 | 0 | -1 |
| Investing Activities | 0 | 0 | -3 | -1 | -3 | -2 | 2 | -2 | 1 | -2 | 0 |
| Financing Activities | 1 | -11 | 10 | -2 | -2 | 2 | -4 | 2 | 1 | 2 | 0 |
| Net Cash Flow | -10 | -2 | -3 | 15 | 0 | -1 | 1 | -1 | -1 | 0 | 0 |